Page 77 - Read Online

Page 4 of 5 Anand et al. Metab Target Organ Damage. 2025;5:20 https://dx.doi.org/10.20517/mtod.2025.18

REFERENCES
1. Lonardo A, Leoni S, Alswat KA, Fouad Y. History of nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21:5888. DOI PubMed
PMC
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
Mayo Clin Proc. 1980;55:434-8. PubMed
3. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986;8:283-98. PubMed
4. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease
(NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-47. DOI PubMed PMC
5. Battistella S, D’Arcangelo F, Grasso M, et al. Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant
management. Clin Mol Hepatol. 2023;29:S286-301. DOI PubMed PMC
6. Daher D, Dahan KSE, Singal AG. Non-alcoholic fatty liver disease-related hepatocellular carcinoma. J Liver Cancer. 2023;23:127-42.
DOI PubMed PMC
7. Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res.
2023;119:1787-98. DOI PubMed PMC
8. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic
associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1. DOI PubMed
9. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new
fatty liver disease nomenclature. Hepatology. 2023;78:1966-86. DOI PubMed PMC
10. Lancet Gastroenterology Hepatology. Redefining non-alcoholic fatty liver disease: what’s in a name? Lancet Gastroenterol Hepatol.
2020;5:419. DOI PubMed
11. Premkumar M, Anand AC. Lean fatty liver disease: through thick and thin. J Clin Exp Hepatol. 2021;11:523-7. DOI PubMed PMC
12. Chen L. From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease:
controversy and consensus. World J Hepatol. 2023;15:1253-7. DOI PubMed PMC
13. Fouad Y. Metabolic-associated fatty liver disease: new nomenclature and approach with hot debate. World J Hepatol. 2023;15:123-8.
DOI PubMed PMC
14. Duseja A, De A, Mehta M, et al. Patients with metabolic-dysfunction associated fatty liver disease (MAFLD) without associated
etiologies and non-MAFLD non-alcoholic fatty liver disease (NAFLD) have similar liver disease severity - data from Indian
Consortium on NAFLD (ICON-D). J Clin Exp Hepatol. 2022;12:S73-4. DOI
15. Gofton C, Upendran Y, Zheng MH, George J. MAFLD: how is it different from NAFLD? Clin Mol Hepatol. 2023;29:S17-31. DOI
PubMed PMC
16. Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2019;1:329-41. DOI PubMed
PMC
17. Singh SP, Anirvan P, Reddy KR, et al. Non-alcoholic fatty liver disease: not time for an obituary just yet! J Hepatol. 2021;74:972-4.
DOI PubMed
18. Duseja A, Taneja S. Changing nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver
disease - not only premature but also confusing. J Clin Exp Hepatol. 2021;11:278-9. DOI PubMed PMC
19. Singh SP, Anirvan P, Butt AS, et al. NAFLD vs MAFLD: South Asian NAFLD patients don’t favor name change. Euroasian J
Hepatogastroenterol. 2022;12:S1-4. DOI PubMed PMC
20. Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: implications of a premature change in terminology.
Hepatology. 2021;73:1194-8. DOI PubMed
21. Society for Paediatric Gastroenterology Hepatology (ESPGHAN) and European Association for the Study of the Liver (EASL), on
behalf of co-authors. Electronic address: j.p.mann@bham.ac.uk; European Society for Paediatric Gastroenterology Hepatology
(ESPGHAN) and European Association for the Study of the Liver (EASL), on behalf of co-authors. Diagnosis of fatty liver in children
should occur in parallel to investigation for other causes of liver disease. Lancet Gastroenterol Hepatol. 2023;8:598-600. DOI
PubMed
22. Singh SP, Sudhamshu KC, Anirvan P, Shrestha A, Mahtab MA. Nonalcoholic fatty liver disease vs metabolic-associated fatty liver
disease vs metabolic dysfunction-associated steatotic liver disease: what’s in the name? Euroasian J Hepatogastroenterol. 2024;14:1-
4. DOI PubMed PMC
23. García-Compeán D, Jiménez-Rodríguez AR. NAFLD vs MAFLD. The evidence-based debate has come. Time to change? Ann
Hepatol. 2022;27:100765. DOI PubMed
24. Anand AC. MASLD, MLA pesarattu and other developments. J Clin Exp Hepatol. 2025;15:102465. DOI PubMed PMC
25. Schuckit MA, Clarke DF, Smith TL, Mendoza LA. Characteristics associated with denial of problem drinking among two generations
of individuals with alcohol use disorders. Drug Alcohol Depend. 2020;217:108274. DOI PubMed PMC
26. Portincasa P. NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care. Intern Emerg Med.
2023;18:993-1006. DOI PubMed PMC